Plavix patent challenged by Aircoat.

Sanofi-Aventis (Paris, France) has been notified that its patent in the UK issued from its European Patent claiming the active ingredient in its Plavix product has been challenged by Aircoat, Ltd., a Scottish company, in a Scottish Court. Sanofi-Aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent.

Sanofi-Aventis

+331-53-77-4223

www.sanofi-aventis.com

COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:	Aircoat, Ltd
Publication:	BIOTECH Patent News
Article Type:	Brief Article
Geographic Code:	4EUFR
Date:	Jan 1, 2005
Words:	57
Previous Article:	Dynogen awarded broad United States patent relating to treatment of lower urinary tract disorders.
Next Article:	Millennium and UCB collaborate on two biotherapeutic inflammation programs.
Topics:	Patent infringement Pharmaceutical industry Cases